Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is *Deramiocel** ( CAP-1002* ), our lead cell therapy in late-stage development for Duchenne muscular dystrophy